Status:
ENROLLING_BY_INVITATION
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage
Lead Sponsor:
Qingwen Tao
Conditions:
Primary Sjögren Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
ChatGPT In a randomized controlled trial, 136 patients with primary Sjögren's syndrome (pSS) meeting the inclusion criteria were enrolled and randomly divided into two groups of 68 each. The treatment...
Eligibility Criteria
Inclusion
- 1\. clinical diagnosis of pSS and qi and yin deficiency ; 2.Sign the informed consent form.
Exclusion
- 1\. pSS activity system damage (ESSDAI score ≥5); 2. Combined connective tissue diseases other than pSS; 3. Pregnant or lactating women; 4. severe cardiovascular and cerebrovascular diseases, liver and kidney failure, and severe malignant tumors; 5. taking psychotropic drugs; 6. assessed by the investigator to be ineligible for enrollment.
Key Trial Info
Start Date :
July 13 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT06519617
Start Date
July 13 2024
End Date
December 31 2026
Last Update
July 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China-Japan friendship hospital
Beijing, Beijing Municipality, China, 100029